Exact Mass: 446.2165
Exact Mass Matches: 446.2165
Found 500 metabolites which its exact mass value is equals to given mass value 446.2165
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Olmesartan
Olmesartan is an antihypertensive agent which belongs to the class of medicines called angiotensin II receptor antagonists. It acts rapidly to lower high blood pressure. It is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. and Forest Laboratories. C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure[1][2].
Tert-Butyl (4-(3-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)isoxazol-5-yl)phenyl)carbamate
(2S,3As,6aS)-1-[(2R)-2-carboxy-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]acetyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
1-Methoxy-3-hydroxy-2-carbomethoxy-9,10-anthraquinone 3-O-beta-primeveroside
(Z)-2,6-dimethyl-7-(4-methyl-5-oxooxolan-2-yl)-3-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]hept-5-enoic acid
16,17-dihydroxy-9,10,12,18-tetramethoxy-5,16-cyclo-corynox-19-en-2-one
linalyl-6-O-(3-hydroxy-3-methylglutaroyl)-beta-D-glucopyranoside
patrinoside-aglycone-11-O-2-deoxy-beta-D-glucopyranoside
(1S,5R,7R,10R)-secoatractylolactone 11-O-beta-D-glucopyranoside|(1S,5R,7R,10R)-Secoatractylolactone 11-O-??-D-glucopyranoside
CAY10603
D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors
C21H34O10_2H-Cyclohepta[b]furan-2-one, 4-acetyl-6-[1-(beta-D-glucopyranosyloxy)-1-methylethyl]octahydro-8a-(hydroxymethyl)-, (3aS,4R,6R,8aR)
C21H34O10_[(1S,5R)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl]methyl 6-O-alpha-L-arabinopyranosyl-beta-D-glucopyranoside
Olmesartan
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure[1][2].
2-[[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-6-[(6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methoxy]oxane-3,4,5-triol
2-[[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-6-[(6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methoxy]oxane-3,4,5-triol_major
(Z)-2,6-dimethyl-7-(4-methyl-5-oxooxolan-2-yl)-3-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]hept-5-enoic acid_major
2-[[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-6-[(6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methoxy]oxane-3,4,5-triol_minor
2-[[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-6-[(6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methoxy]oxane-3,4,5-triol_83.2\\%
Ala Asp Lys Asn
Ala Asp Asn Lys
Ala Lys Asp Asn
Ala Lys Asn Asp
Ala Asn Asp Lys
Ala Asn Lys Asp
Ala Asn Arg Ser
Ala Asn Ser Arg
Ala Pro Pro Tyr
Ala Pro Tyr Pro
Ala Gln Gln Thr
Ala Gln Thr Gln
Ala Arg Asn Ser
Ala Arg Ser Asn
Ala Ser Asn Arg
Ala Ser Arg Asn
Ala Thr Gln Gln
Ala Tyr Pro Pro
Asp Ala Lys Asn
Asp Ala Asn Lys
Asp Gly Lys Gln
Asp Gly Gln Lys
Asp Lys Ala Asn
Asp Lys Gly Gln
Asp Lys Asn Ala
Asp Lys Gln Gly
Asp Asn Ala Lys
Asp Asn Lys Ala
Asp Gln Gly Lys
Asp Gln Lys Gly
Glu Gly Lys Asn
Glu Gly Asn Lys
Glu Lys Gly Asn
Glu Lys Asn Gly
Glu Asn Gly Lys
Glu Asn Lys Gly
Phe Pro Pro Ser
Phe Pro Ser Pro
Phe Ser Pro Pro
Gly Asp Lys Gln
Gly Asp Gln Lys
Gly Glu Lys Asn
Gly Glu Asn Lys
Gly Gly Lys Trp
Gly Gly Trp Lys
Gly Lys Asp Gln
Gly Lys Glu Asn
Gly Lys Gly Trp
Gly Lys Asn Glu
Gly Lys Gln Asp
Gly Lys Trp Gly
Gly Asn Glu Lys
Gly Asn Lys Glu
Gly Asn Arg Thr
Gly Asn Thr Arg
Gly Gln Asp Lys
Gly Gln Lys Asp
Gly Gln Arg Ser
Gly Gln Ser Arg
Gly Arg Asn Thr
Gly Arg Gln Ser
Gly Arg Ser Gln
Gly Arg Thr Asn
Gly Ser Gln Arg
Gly Ser Arg Gln
Gly Thr Asn Arg
Gly Thr Arg Asn
Gly Trp Gly Lys
Gly Trp Lys Gly
His Pro Pro Pro
Ile Met Pro Ser
Ile Met Ser Pro
Ile Asn Asn Ser
Ile Asn Ser Asn
Ile Pro Met Ser
Ile Pro Ser Met
Ile Ser Met Pro
Ile Ser Asn Asn
Ile Ser Pro Met
Lys Ala Asp Asn
Lys Ala Asn Asp
Lys Asp Ala Asn
Lys Asp Gly Gln
Lys Asp Asn Ala
Lys Asp Gln Gly
Lys Glu Gly Asn
Lys Glu Asn Gly
Lys Gly Asp Gln
Lys Gly Glu Asn
Lys Gly Gly Trp
Lys Gly Asn Glu
Lys Gly Gln Asp
Lys Gly Trp Gly
Lys Asn Ala Asp
Lys Asn Asp Ala
Lys Asn Glu Gly
Lys Asn Gly Glu
Lys Gln Asp Gly
Lys Gln Gly Asp
Lys Trp Gly Gly
Leu Met Pro Ser
Leu Met Ser Pro
Leu Asn Asn Ser
Leu Asn Ser Asn
Leu Pro Met Ser
Leu Pro Ser Met
Leu Ser Met Pro
Leu Ser Asn Asn
Leu Ser Pro Met
Met Ile Pro Ser
Met Ile Ser Pro
Met Leu Pro Ser
Met Leu Ser Pro
Met Pro Ile Ser
Met Pro Leu Ser
Met Pro Ser Ile
Met Pro Ser Leu
Met Pro Thr Val
Met Pro Val Thr
Met Ser Ile Pro
Met Ser Leu Pro
Met Ser Pro Ile
Met Ser Pro Leu
Met Thr Pro Val
Met Thr Val Pro
Met Val Pro Thr
Met Val Thr Pro
Asn Ala Asp Lys
Asn Ala Lys Asp
Asn Ala Arg Ser
Asn Ala Ser Arg
Asn Asp Ala Lys
Asn Asp Lys Ala
Asn Glu Gly Lys
Asn Glu Lys Gly
Asn Gly Glu Lys
Asn Gly Lys Glu
Asn Gly Arg Thr
Asn Gly Thr Arg
Asn Ile Asn Ser
Asn Ile Ser Asn
Asn Lys Ala Asp
Asn Lys Asp Ala
Asn Lys Glu Gly
Asn Lys Gly Glu
Asn Leu Asn Ser
Asn Leu Ser Asn
Asn Asn Ile Ser
Asn Asn Leu Ser
Asn Asn Ser Ile
Asn Asn Ser Leu
Asn Asn Thr Val
Asn Asn Val Thr
Asn Gln Ser Val
Asn Gln Val Ser
Asn Arg Ala Ser
Asn Arg Gly Thr
Asn Arg Ser Ala
Asn Arg Thr Gly
Asn Ser Ala Arg
Asn Ser Ile Asn
Asn Ser Leu Asn
Asn Ser Asn Ile
Asn Ser Asn Leu
Asn Ser Gln Val
Asn Ser Arg Ala
Asn Ser Val Gln
Asn Thr Gly Arg
Asn Thr Asn Val
Asn Thr Arg Gly
Asn Thr Val Asn
Asn Val Asn Thr
Asn Val Gln Ser
Asn Val Ser Gln
Asn Val Thr Asn
Pro Ala Pro Tyr
Pro Ala Tyr Pro
Pro Phe Pro Ser
Pro Phe Ser Pro
Pro His Pro Pro
Pro Ile Met Ser
Pro Ile Ser Met
Pro Leu Met Ser
Pro Leu Ser Met
Pro Met Ile Ser
Pro Met Leu Ser
Pro Met Ser Ile
Pro Met Ser Leu
Pro Met Thr Val
Pro Met Val Thr
Pro Pro Ala Tyr
Pro Pro Phe Ser
Pro Pro His Pro
Pro Pro Pro His
Pro Pro Ser Phe
Pro Pro Tyr Ala
Pro Ser Phe Pro
Pro Ser Ile Met
Pro Ser Leu Met
Pro Ser Met Ile
Pro Ser Met Leu
Pro Ser Pro Phe
Pro Thr Met Val
Pro Thr Val Met
Pro Val Met Thr
Pro Val Thr Met
Pro Tyr Ala Pro
Pro Tyr Pro Ala
Gln Ala Gln Thr
Gln Ala Thr Gln
Gln Asp Gly Lys
Gln Asp Lys Gly
Gln Gly Asp Lys
Gln Gly Lys Asp
Gln Gly Arg Ser
Gln Gly Ser Arg
Gln Lys Asp Gly
Gln Lys Gly Asp
Gln Asn Ser Val
Gln Asn Val Ser
Gln Gln Ala Thr
Gln Gln Thr Ala
Gln Arg Gly Ser
Gln Arg Ser Gly
Gln Ser Gly Arg
Gln Ser Asn Val
Gln Ser Arg Gly
Gln Ser Val Asn
Gln Thr Ala Gln
Gln Thr Gln Ala
Gln Val Asn Ser
Gln Val Ser Asn
Arg Ala Asn Ser
Arg Ala Ser Asn
Arg Gly Asn Thr
Arg Gly Gln Ser
Arg Gly Ser Gln
Arg Gly Thr Asn
Arg Asn Ala Ser
Arg Asn Gly Thr
Arg Asn Ser Ala
Arg Asn Thr Gly
Arg Gln Gly Ser
Arg Gln Ser Gly
Arg Ser Ala Asn
Arg Ser Gly Gln
Arg Ser Asn Ala
Arg Ser Gln Gly
Arg Thr Gly Asn
Arg Thr Asn Gly
Ser Ala Asn Arg
Ser Ala Arg Asn
Ser Phe Pro Pro
Ser Gly Gln Arg
Ser Gly Arg Gln
Ser Ile Met Pro
Ser Ile Asn Asn
Ser Ile Pro Met
Ser Leu Met Pro
Ser Leu Asn Asn
Ser Leu Pro Met
Ser Met Ile Pro
Ser Met Leu Pro
Ser Met Pro Ile
Ser Met Pro Leu
Ser Asn Ala Arg
Ser Asn Ile Asn
Ser Asn Leu Asn
Ser Asn Asn Ile
Ser Asn Asn Leu
Ser Asn Gln Val
Ser Asn Arg Ala
Ser Asn Val Gln
Ser Pro Phe Pro
Ser Pro Ile Met
Ser Pro Leu Met
Ser Pro Met Ile
Ser Pro Met Leu
Ser Pro Pro Phe
Ser Gln Gly Arg
Ser Gln Asn Val
Ser Gln Arg Gly
Ser Gln Val Asn
Ser Arg Ala Asn
Ser Arg Gly Gln
Ser Arg Asn Ala
Ser Arg Gln Gly
Ser Val Asn Gln
Ser Val Gln Asn
Thr Ala Gln Gln
Thr Gly Asn Arg
Thr Gly Arg Asn
Thr Met Pro Val
Thr Met Val Pro
Thr Asn Gly Arg
Thr Asn Asn Val
Thr Asn Arg Gly
Thr Asn Val Asn
Thr Pro Met Val
Thr Pro Val Met
Thr Gln Ala Gln
Thr Gln Gln Ala
Thr Arg Gly Asn
Thr Arg Asn Gly
Thr Val Met Pro
Thr Val Asn Asn
Thr Val Pro Met
Val Met Pro Thr
Val Met Thr Pro
Val Asn Asn Thr
Val Asn Gln Ser
Val Asn Ser Gln
Val Asn Thr Asn
Val Pro Met Thr
Val Pro Thr Met
Val Gln Asn Ser
Val Gln Ser Asn
Val Ser Asn Gln
Val Ser Gln Asn
Val Thr Met Pro
Val Thr Asn Asn
Val Thr Pro Met
Trp Gly Gly Lys
Trp Gly Lys Gly
Trp Lys Gly Gly
Tyr Ala Pro Pro
Tyr Pro Ala Pro
Tyr Pro Pro Ala
(S)-1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethylaMine N-acetyl-L-leucine salt
[(3aR,4R,5R,6aS)-2-oxo-4-(3-oxooct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-yl] 4-phenylbenzoate
3-Cyclohexyl-1-(2-morpholin-4-YL-2-oxoethyl)-2-phenyl-1H-indole-6-carboxylic acid
1-[(1R)-3-(6-{[(Benzylamino)carbonyl]amino}-1H-indol-1-YL)-1-(hydroxymethyl)propyl]-1H-imidazole-4-carboxamide
2-Butoxy-9-(2,6-Difluorobenzyl)-N-(2-Morpholin-4-Ylethyl)-9h-Purin-6-Amine
N-[(13-Cyclohexyl-6,7-Dihydroindolo[1,2-D][1,4]benzoxazepin-10-Yl)carbonyl]-2-Methyl-L-Alanine
(2S,3As,6aS)-1-[(2R)-2-carboxy-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]acetyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
8,9-dimethyl-N-(3-methylphenyl)-3-[2-(4-morpholinyl)ethyl]-4H-[1,3]thiazino[6,5-b]quinolin-2-imine
methyl 6-O-alpha-L-arabinopyranosyl-6-C-[(1S,5R)-6,6-dimethylbicyclo[3.1.1]heptan-2-ylidene]-beta-L-idopyranoside
1,3-benzodioxol-5-yl-[(2R,3R)-1-(cyclopropylmethyl)-2-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazaspiro[3.3]heptan-6-yl]methanone
1-(1,3-benzodioxol-5-yl)-3-[(2S,3S,6S)-6-[2-[4-[(dimethylamino)methyl]-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]urea
1-(1,3-benzodioxol-5-yl)-3-[(2S,3S,6R)-6-[2-[4-[(dimethylamino)methyl]-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]urea
[(3aR,4R,9bR)-4-(hydroxymethyl)-8-[2-(4-methoxyphenyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-(4-oxanyl)methanone
(6R,7R,8S)-8-(hydroxymethyl)-4-(oxane-4-carbonyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-8-(hydroxymethyl)-4-(oxane-4-carbonyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-8-(hydroxymethyl)-4-(oxane-4-carbonyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
1-(1,3-benzodioxol-5-yl)-3-[(2S,3R,6S)-6-[2-[4-[(dimethylamino)methyl]-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]urea
1-(1,3-benzodioxol-5-yl)-3-[(2R,3S,6R)-6-[2-[4-[(dimethylamino)methyl]-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]urea
1-(1,3-benzodioxol-5-yl)-3-[(2S,3R,6R)-6-[2-[4-[(dimethylamino)methyl]-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]urea
1-(1,3-benzodioxol-5-yl)-3-[(2R,3R,6R)-6-[2-[4-[(dimethylamino)methyl]-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]urea
1-(1,3-benzodioxol-5-yl)-3-[(2R,3S,6S)-6-[2-[4-[(dimethylamino)methyl]-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]urea
1-(1,3-benzodioxol-5-yl)-3-[(2R,3R,6S)-6-[2-[4-[(dimethylamino)methyl]-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]urea
[(3aR,4R,9bS)-8-(1-cyclohexenyl)-4-(hydroxymethyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-(1,3-benzodioxol-5-yl)methanone
[(3aS,4S,9bS)-4-(hydroxymethyl)-8-[2-(4-methoxyphenyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-(4-oxanyl)methanone
1,3-benzodioxol-5-yl-[(2S,3S)-1-(cyclopropylmethyl)-2-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazaspiro[3.3]heptan-6-yl]methanone
(6S,7R,8R)-8-(hydroxymethyl)-4-(oxane-4-carbonyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8S)-8-(hydroxymethyl)-4-(oxane-4-carbonyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-8-(hydroxymethyl)-4-(oxane-4-carbonyl)-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
8-methoxy-3-[(E)-[4-methoxy-3-(pyrrolidin-1-ylmethyl)phenyl]methylideneamino]-2-methyl-5H-pyrimido[5,4-b]indol-1-ium-4-one
(3aalpha,4R)-4alpha-Acetyl-6alpha-[1-methyl-1-(beta-D-glucopyranosyloxy)ethyl]-8aalpha-(hydroxymethyl)octahydro-2H-cyclohepta[b]furan-2-one
(1-acetyloxy-3-phosphonooxypropan-2-yl) (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
phosphatidic acid 18:3
A phosphatidic acid in which the two acyl groups contain a total of 18 carbons and 3 double bonds.
pinen-10-yl vicianoside
A monoterpene glycoside with formula C21H34O10, originally isolated from the roots of Paeonia lactiflora.
Fumarate hydratase-IN-1
Fumarate hydratase-IN-1 (compound 2) is a cell-permeable fumarate hydratase inhibitor. Fumarate hydratase-IN-1 has antiproliferative activity against several cancer cell lines with a mean IC50 of 2.2 μM[1].
VU0364739
VU0364739 is a selective PLD2 inhibitor (IC50: 22 nM). VU0364739 decreases cancer cell proliferation[1].